Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events | Synapse
April 12, 2026Open Access
Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events
Key Points
This analysis aims to evaluate the short-term and long-term safety of brexpiprazole in treating agitation linked to Alzheimer's disease.
Post hoc analysis of multiple clinical trials
Examination of adverse events associated with brexpiprazole
Focus on timing and duration of reported effects
Identified specific adverse events related to brexpiprazole
Assessed both short-term and long-term safety profiles
Provided insights into the timing of adverse events for better patient management
Abstract
Post hoc analysis of NCT01862640, NCT01922258, NCT03548584, NCT03594123 (ClinicalTrials.gov).